SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention after its CEOs anniversary message prompted renewed speculation about a potential buyout, alongside anticipation for the final analysis of its Phase 3 REGAL leukemia trial, which requires 80 events and was last reported at 78. Traders disagree on whether the message and prolonged trial timeline signal favorable data or a deal; neither a buyout nor a trial outcome has been confirmed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude swings on fears of Middle East supply disruptions, including reported attacks on shipping and energy infrastructure and heightened Iran-US tensions. Traders are divided between bulls focused on geopolitical supply risks and bears who see peace-deal headlines, disputed reports, or a normalization of flows unwinding the oil premium.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff is drawing attention amid HSBCs bearish assessment and concerns about heavy debt, borrowing costs and access to financing for its AI infrastructure expansion. Traders are divided between expecting further downside and betting on a rebound or short squeeze; some bulls point to reported GPU price increases as evidence of demand and pricing power.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff and weak performance versus peers as traders debate neocloud financing risks and broader concerns about AI infrastructure spending. The co-CEOs statement that data centers carry no debt and customer prepayments help fund GPU costs has reassured some investors, while others remain concerned about execution and the stocks continued weakness.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound from recent lows and its struggle to clear near-term resistance are driving discussion, with traders debating whether the move can extend or fade into another pullback. Bulls see potential for a short squeeze, while skeptics call the bounce a trap and point to weak demand and macro uncertainty.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price underperformance and widespread frustration with managements shift toward external acquisitions and pipeline investment, which critics fear could add debt and dilution. Bulls point to Orladeyos revenue and upcoming Netherton and Navenibart data, while bearish traders question whether those prospects can restore confidence.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows has focused discussion on waning confidence in Trump ahead of the midterms and concerns about Truth Socials engagement and the companys underlying business. Bearish traders see room for further declines, while some view the selloff as an opportunity for a short-term bounce.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians reported Q3 outlook increase and reaffirmation of its 2026 outlook, alongside Carnivals strong results lifting cruise shares, are driving renewed interest. Bulls point to resilient bookings and heavy short interest as reasons for optimism, while others remain cautious about fuel costs, debt, and NCLHs lagging performance versus peers; squeeze talk is speculative.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed reports of a possible US-Iran dealand a pullback in oil pricesare widely cited as drivers of QQQs sharp rebound and volatile swings. Traders disagree over whether the rally is durable or a headline-driven bull trap, while upcoming big-tech earnings and AI-sector weakness add uncertainty.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

SE is drawing attention for a sharp pullback despite strong Q2 growth; traders blame insider share sales and technical weakness, while bulls argue the sales were planned and point to Shopee and Monee growth as reasons to buy the dip.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Momentum Stocks to Buy for September 17th

MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.

New Strong Buy Stocks for September 17th

MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

5 Stocks With Recent Price Strength Buoyed by a Strong August

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.


Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going

Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Best Momentum Stocks to Buy for August 25th

LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.

New Strong Buy Stocks for August 25th

IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Assembly Biosciences Inc

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Gilead will advance the clinical development and commercialization of the programs and Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option.</li><li>H.C. Wainwright believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."</li><li>According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes.</li></ul>Shares of Assembly Biosciences Inc closed up 3% on Monday after Gilead Sciences exercised the option to license the company’s programs for recurrent genital herpes in a move applauded by Wall Street. &nbsp;The programs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.gilead.com/news/news-details/2025/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes"> include</a> investigational candidates ABI-1179 and ABI-5366. Gilead will advance the clinical development and commercialization of the programs under its ongoing collaboration with Assembly Bio which was inked in 2023 and spans 12 years. Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option and remains eligible for up to $330 million in regulatory and commercial milestones, as well as tiered royalties on net sales.H.C. Wainwright analyst Patrick Trucchio subsequently reiterated a ‘Buy’ rating on Assembly Biosciences (ASMB) with a $50 price target. The analyst believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."<h2 class="st-heading-2">About The Programs</h2>Genital herpes is a common sexually transmitted infection (STI) caused by the herpes simplex virus (HSV), leading to painful blisters and sores around the genitals or anus, though many people have mild or no symptoms and don't know they're infected. Spread through skin-to-skin contact, especially during sex, the virus stays in the body, causing recurring outbreaks triggered by stress, illness, or fatigue.According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes. No new therapies have been approved for HSV in the U.S. or Europe for more than 25 years, the company noted.ABI-1179 and ABI-5366 are novel long-acting inhibitors of viral helicase-primase, an enzyme essential for herpes virus replication. Positive interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated strong antiviral activity and improvements in clinical outcomes, including significant reduction in virus-positive lesions, the company noted. Both compounds also exhibit pharmacokinetic and safety profiles supportive of once-weekly oral dosing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/ASMB"> ASMB </a>rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.Sentiment around GILD stayed within the 'neutral' territory in the meantime.<a href="https://stocktwits.com/symbol/GILD">Shares of GILD</a> have risen nearly 34% this year while ASMB shares have more than doubled.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-rival-ula-ceo-tory-bruno-steps-down/cLeFtcyREub">SpaceX Rival ULA CEO Tory Bruno Steps Down After 12 Years — Says ‘My Work Here Is Now Complete’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.

Gilead Sciences, Inc.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Stocktwits Polls

$ASMB  This stock means more to me than just a possible financial gain, my wife died from PBC. Even after a liver transplant the PBC came back to claim her life. It would be fantastic if a treatment became available for women suffering from PBC. I have invested a great deal of my money into viking stock. She was a hellofagirl! 
Best of luck to everyone who believes in this company.

Hella

$ASMB presented positive Phase 1a safety and target engagement data for ABI-6250 at AASLD The Liver Meeting.

jorge .miguel

$ASMB am 15.10 endet die stillhalte zeit.es kann wieder öffentlich komuniziert werden.viele denken dann kommt ein übernahmeangebot von giliad.

Helmut Renus

$ASMB so unbelievable. Every day the shorts are bringing it down at open 🤦 wish for their ass to itch and their arms to be too short!!

$ASMB manipulate the stock price as long as possible pls. That’s the biggest benefit for buyer currently 😄

Shin Chan

$ASMB Solid buying at the end of the day. I'm confident the stock will start rising again now.  Starting October 15, the next 75 million from $GILD will be transferred, and the Class B warrants will be canceled.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ASMB Assembly Biosciences Inc

Fundamentals

Latest ASMB News